1. Medtech Insight
  2. >>Device Area
  3. >>Diagnostics
  4. >>In Vitro Diagnostics

'App-A-Thon' Aims To Create PrecisionFDA Software Library To Advance Next-Gen Sequencing

US FDA is challenging stakeholders to develop apps that users of its precisionFDA platform can leverage to advance next-generation sequencing technology. Results from the competition will be announced by Commissioner Robert Califf next month in Washington, DC.

In its bid to advance next-generation sequencing technology, US FDA is encouraging software developers to enter a competition to develop apps for the agency's precisionFDA NGS data-sharing platform.

The presicionFDA portal was launched late last year as a tool to allow researchers to share information on NGS data...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from In Vitro Diagnostics

MCED Act Advances In US House Committees, Exact Sciences Cancerguard Poised To Benefit

 
• By Natasha Barrow

The Nancy Gardner Sewell MCED Act has advanced in the US House, potentially allowing Medicare coverage for multi-cancer early detection tests. Exact Sciences is targeting FDA approval for its MCED test Cancerguard, launched in the US earlier this month.

Arima Genomics’ CEO Sets Sight On Replacing Standard Testing With 3D Genomics Lymphoma Assay

 
• By Marion Webb

Arima Genomics launched its new Aventa Lymphoma test aimed at helping pathologists detect lymphomas missed by standard FISH analysis. Initially positioned as complementary technology, Arima hopes to become the new standard test.

Salient Bio Raises £2.35M For March 2026 Rollout Of At-Home IBD Microbiome Test

 
• By Natasha Barrow

Salient's inflammatory bowel disease test, built on the start-up’s Signal platform, is planned to launch in March 2026. The company leverages rich data from existing wellness tests to develop signatures, focusing on conditions that are often misdiagnosed and disproportionately affect women.

Government-Backed UK Network Enhances Access To Clinical Trials

 
• By Vibha Sharma

The UK government expects that its new nation-wide network will enable companies to set up clinical trials more quickly and expand access to diverse patient populations across the National Health Service.

More from Diagnostics

Whistleblower Suit Against UnitedHealth Continues After Semler, Bard Settle Related Cases

 
• By Elizabeth Orr

Insurance firm UnitedHealth is facing allegations the company intentionally used an unreliable PAD screening method to increase its reimbursements under Medicare Advantage. Semler Scientific and Bard, which respectively made and manufactured the products in question, settled related cases for $37m.

‘Much-Needed Tool For Large Tissue Biopsy’: Resitu Medical’s Breast Device FDA Authorized

 
• By Natasha Barrow

Resitu Medical has received FDA 510(k) authorization for the RESL09 breast cancer biopsy device. This handheld minimally invasive device excises tissue samples with diameters up to 9 mm and will first reach market in the US. The company plans to expand the tool’s clinical claims and core size range.

MCED Act Advances In US House Committees, Exact Sciences Cancerguard Poised To Benefit

 
• By Natasha Barrow

The Nancy Gardner Sewell MCED Act has advanced in the US House, potentially allowing Medicare coverage for multi-cancer early detection tests. Exact Sciences is targeting FDA approval for its MCED test Cancerguard, launched in the US earlier this month.